Last reviewed · How we verify
GW427353
At a glance
| Generic name | GW427353 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women (PHASE2)
- A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) (PHASE2)
- Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects (PHASE1)
- A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder (PHASE1)
- A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS) (PHASE2)
- Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms (PHASE2)
- A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers (PHASE1)
- A Two-Part Study to Determine: Best Medication Formulation and Food Effect (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW427353 CI brief — competitive landscape report
- GW427353 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI